Enlaza Therapeutics Inc. will take charge of research through nominating candidates in its potentially $2 billion-plus deal with Vertex Pharmaceuticals Inc. For its efforts, Enlaza is getting $45 ...
Copilot is on the way to Microsoft Excel. Or rather, more Copilot is being packed into the popular spreadsheet program. A new COPILOT function is rolling out now to users in the Beta Channel and ...
Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...
After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Have you ever been overwhelmed by messy spreadsheets or struggled to collect data in an organized way? Imagine a scenario where instead of juggling multiple tabs and rows, you could guide users ...
BOSTON, July 14, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a ...
Multiple sclerosis isn’t inherited, but having a family member with the disease can increase your chance of having the condition. While genetics influences your risk, environmental factors also play a ...
During Florida Institute of Technology President John Nicklow's interview activities leading up to his April 2023 hiring, he toured CAMID, the university's sprawling 100,494-square-foot ...
The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback